Encouraging Survival Data For Lynparza in Metastatic Breast Cancer

16 Apr 2018

• By John Davis

OlympiAD data update backs AZ/Merck & Co.'s PARP inhibitor in metastatic breast cancer, but study not powered to give definitive answer about its effects on overall survival.

Breast carcinoma — Inflammatory breast carcinoma tissue • Source: Shutterstock

Although the Phase III OlympiAD study wasn't powered to show a statistically significant effect on survival, updated overall survival (OS) data from the trial are "another encouraging marker" for the use of AstraZeneca PLC/Merck & Co. Inc.'s PARP inhibitor, Lynparza (olaparib) in BRCA-mutated, HER2-negative metastatic breast cancer, the companies say.

The final OS results from the OlympiAD study found that Lynparza therapy was associated with a median OS of 19.3...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Santen Sees Potential In Myopia Market After Ryjunea Approval

06 Jun 2025

• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

06 Jun 2025

• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

06 Jun 2025

• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

06 Jun 2025

• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

05 Jun 2025

• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.